EA035733B9 - Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний - Google Patents

Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний

Info

Publication number
EA035733B9
EA035733B9 EA201890325A EA201890325A EA035733B9 EA 035733 B9 EA035733 B9 EA 035733B9 EA 201890325 A EA201890325 A EA 201890325A EA 201890325 A EA201890325 A EA 201890325A EA 035733 B9 EA035733 B9 EA 035733B9
Authority
EA
Eurasian Patent Office
Prior art keywords
interleukin
receptor
peptide inhibitors
inflammatory diseases
treat inflammatory
Prior art date
Application number
EA201890325A
Other languages
English (en)
Russian (ru)
Other versions
EA201890325A1 (ru
EA035733B1 (ru
Inventor
Грегори Борн
Сяоли Чэн
Брайан Трой Фредерик
Цзе Чжан
Динеш В. Пател
Дэвид Лю
Ашок Бхандари
Original Assignee
Протагонист Терепьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/800,627 external-priority patent/US9624268B2/en
Application filed by Протагонист Терепьютикс, Инк. filed Critical Протагонист Терепьютикс, Инк.
Publication of EA201890325A1 publication Critical patent/EA201890325A1/ru
Publication of EA035733B1 publication Critical patent/EA035733B1/ru
Publication of EA035733B9 publication Critical patent/EA035733B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EA201890325A 2015-07-15 2016-07-15 Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний EA035733B9 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14/800,627 US9624268B2 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PCT/US2015/040658 WO2016011208A1 (fr) 2014-07-17 2015-07-15 Peptides inhibiteurs par voie orale du récepteur de l'interleukine-23 et leur utilisation dans le traitement des maladies inflammatoires de l'intestin
US201562264820P 2015-12-08 2015-12-08
US201662281123P 2016-01-20 2016-01-20
PCT/US2016/042680 WO2017011820A2 (fr) 2015-07-15 2016-07-15 Peptides inhibiteurs du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires

Publications (3)

Publication Number Publication Date
EA201890325A1 EA201890325A1 (ru) 2018-06-29
EA035733B1 EA035733B1 (ru) 2020-07-31
EA035733B9 true EA035733B9 (ru) 2021-01-14

Family

ID=57757647

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890325A EA035733B9 (ru) 2015-07-15 2016-07-15 Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний

Country Status (23)

Country Link
EP (1) EP3341011A4 (fr)
JP (1) JP6858174B2 (fr)
KR (1) KR102513978B1 (fr)
CN (1) CN108348580B (fr)
AU (1) AU2016293619B2 (fr)
BR (1) BR112018000691A2 (fr)
CA (1) CA2991984A1 (fr)
CL (3) CL2018000128A1 (fr)
CO (1) CO2018000349A2 (fr)
CR (1) CR20180029A (fr)
DO (1) DOP2018000010A (fr)
EA (1) EA035733B9 (fr)
EC (1) ECSP18002929A (fr)
HK (1) HK1257747A1 (fr)
IL (1) IL256827A (fr)
MX (1) MX384213B (fr)
NI (1) NI201800008A (fr)
PE (1) PE20180571A1 (fr)
PH (1) PH12018500086A1 (fr)
SG (1) SG10201912066SA (fr)
SV (1) SV2018005614A (fr)
UA (1) UA123772C2 (fr)
WO (1) WO2017011820A2 (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58514B1 (sr) 2012-06-13 2019-04-30 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
EP4091624A1 (fr) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Analogues d'hepcidine et leurs utilisations
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
WO2016054411A1 (fr) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOUVEAUX ANTAGONISTES PEPTIDIQUES MONOMÈRES ET DIMÈRES DE α4β7
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3017926C (fr) 2016-03-23 2023-10-10 Protagonist Therapeutics, Inc. Procedes de synthese d'antagonistes de peptide .alpha.4.beta.7
WO2018136646A1 (fr) 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptides inhibiteurs du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
EP3681900A4 (fr) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. Peptides d'agoniste opioïde et leurs utilisations
CA3089868A1 (fr) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Mimetiques d'hepcidine conjugues
HRP20241288T1 (hr) 2018-05-04 2024-12-06 Incyte Corporation Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
WO2020014646A1 (fr) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN110015978B (zh) * 2019-04-29 2021-03-19 康化（上海）新药研发有限公司 O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的合成方法
US20220251185A1 (en) * 2019-07-01 2022-08-11 Valitor, Inc. Hydrophilic linkers for multivalent peptide conjugates
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP7534382B2 (ja) * 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
WO2021067374A1 (fr) 2019-10-01 2021-04-08 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
CA3157361A1 (fr) 2019-10-14 2021-04-22 Incyte Corporation Heterocycles bicycliques utilises en tant qu'inhibiteurs de fgfr
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
EP3819307A1 (fr) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Dérivés thérapeutiques de l'interleukine-22
JP7832891B2 (ja) 2019-12-04 2026-03-18 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
CA3163875A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
CA3167751A1 (fr) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Inhibiteurs peptidiques du recepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2021209086A1 (en) * 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021301192A1 (en) * 2020-06-29 2023-02-02 University Of Washington Human IL23 receptor binding polypeptides
JP2023542867A (ja) 2020-09-11 2023-10-12 グリンプス バイオ， インコーポレイテッド 疾患の検出／診断、病期分類、モニタリング及び処置のための生体外でのプロテアーゼ活性検出
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
JP2023145581A (ja) * 2020-11-20 2023-10-11 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
WO2022221170A1 (fr) 2021-04-12 2022-10-20 Incyte Corporation Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CA3220155A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Heterocycles tricycliques utiles en tant qu'inhibiteurs de fgfr
EP4370146A4 (fr) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Inhibiteurs peptidiques lipidés du récepteur de l'interleukine-23
TW202332683A (zh) * 2021-07-14 2023-08-16 美商健生生物科技公司 介白素－２３受體之肽抑制劑
EP4370532A4 (fr) * 2021-07-14 2025-09-03 Janssen Biotech Inc Inhibiteurs peptidiques bicycliques du récepteur de l'interleukine-23
AU2022402440A1 (en) 2021-12-01 2024-05-30 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2023172648A2 (fr) * 2022-03-09 2023-09-14 Glympse Bio, Inc. Substrats fluorogènes pour la détection d'aminopeptidase dans des fluides biologiques
CN114751962B (zh) * 2022-03-17 2023-11-07 北京大学 订书肽、其制备方法及其制药用途
CA3260606A1 (fr) 2022-06-30 2024-01-04 Sanofi Nouveaux peptides à utiliser en tant qu'antagonistes sélectifs du récepteur de l'il-23
WO2024110477A2 (fr) * 2022-11-21 2024-05-30 Janssen Pharmaceutica Nv Synthèse d'un peptide cyclique
US20240279281A1 (en) * 2023-01-16 2024-08-22 Janssen Pharmaceutica Nv Peptide Inhibitors of Interleukin-23 Receptor
EP4652180A2 (fr) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Inhibiteurs peptidiques du récepteur de l'interleukine-23
WO2024155551A1 (fr) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Inhibiteurs peptidiques polycycliques du récepteur de l'interleukine-23
IL322423A (en) 2023-01-31 2025-09-01 Janssen Pharmaceutica Nv Methods for preparing crystalline peptide inhibitors of the interleukin-23 receptor
CN121443624A (zh) * 2023-05-04 2026-01-30 西藏海思科制药有限公司 白介素-23受体的肽抑制剂制备及其用途
EP4471049A1 (fr) 2023-06-01 2024-12-04 Zealand Pharma A/S Inhibiteurs peptidiques du récepteur de l'interleukine-23
EP4471048A1 (fr) 2023-06-01 2024-12-04 Zealand Pharma A/S Inhibiteurs peptidiques du récepteur de l'interleukine-23
CN121794283A (zh) 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
CN121909205A (zh) 2023-09-08 2026-04-21 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2026013260A1 (fr) 2024-07-12 2026-01-15 Zealand Pharma A/S Inhibiteurs peptidiques du récepteur de l'interleukine-23
WO2026057052A1 (fr) * 2024-09-14 2026-03-19 深圳信立泰药业股份有限公司 Inhibiteur du récepteur de l'il-23, son procédé de préparation et son utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166514A1 (en) * 1996-11-12 2003-09-04 Jones Terence R. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US20100190710A1 (en) * 2007-07-06 2010-07-29 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
US20130172272A1 (en) * 2011-06-14 2013-07-04 Medical Diagnostic Laboratories Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2677932A1 (fr) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Co-agonistes des recepteurs du glucagon/glp-1
CA2707840A1 (fr) 2007-08-20 2009-02-26 Allozyne, Inc. Molecules substituees par des acides amines
US10416172B2 (en) 2010-03-31 2019-09-17 Medical Diagnostic Laboratories, Llc Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling
US8946150B2 (en) * 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US20160235807A1 (en) * 2013-10-09 2016-08-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166514A1 (en) * 1996-11-12 2003-09-04 Jones Terence R. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US20100190710A1 (en) * 2007-07-06 2010-07-29 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
US20130172272A1 (en) * 2011-06-14 2013-07-04 Medical Diagnostic Laboratories Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof

Also Published As

Publication number Publication date
CL2021000343A1 (es) 2021-08-06
CO2018000349A2 (es) 2018-07-10
HK1259149A1 (zh) 2019-11-29
IL256827A (en) 2018-03-29
HK1257747A1 (zh) 2019-10-25
ECSP18002929A (es) 2018-03-31
UA123772C2 (uk) 2021-06-02
JP2018522008A (ja) 2018-08-09
WO2017011820A3 (fr) 2017-02-23
KR20180030663A (ko) 2018-03-23
AU2016293619A1 (en) 2018-02-01
EP3341011A4 (fr) 2019-02-20
DOP2018000010A (es) 2018-03-30
MX2018000542A (es) 2018-06-27
MX384213B (es) 2025-03-14
NI201800008A (es) 2018-06-29
CN108348580B (zh) 2022-05-10
EA201890325A1 (ru) 2018-06-29
SG10201912066SA (en) 2020-02-27
CA2991984A1 (fr) 2017-01-19
CN108348580A (zh) 2018-07-31
JP6858174B2 (ja) 2021-04-14
EA035733B1 (ru) 2020-07-31
AU2016293619B2 (en) 2021-02-25
CL2018000128A1 (es) 2018-06-15
EP3341011A2 (fr) 2018-07-04
CL2018003322A1 (es) 2019-01-18
BR112018000691A2 (pt) 2018-09-18
CR20180029A (es) 2018-06-05
WO2017011820A2 (fr) 2017-01-19
PE20180571A1 (es) 2018-04-04
SV2018005614A (es) 2018-05-22
PH12018500086A1 (en) 2018-07-30
KR102513978B1 (ko) 2023-03-27

Similar Documents

Publication Publication Date Title
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP4378536A3 (fr) Inhibiteurs peptidiques oraux du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies intestinales inflammatoires
MX2022000397A (es) Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
ZA202004557B (en) Modulatory polynucleotides
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
MX2020011749A (es) Composiciones y metodos para modular la expresion de pkk.
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
PH12016501702B1 (en) Pyrazole amide derivative
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2020011668A (es) Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
EA201791937A1 (ru) Противовоспалительные полипептиды
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM